SCHEMBL16277191

SCHEMBL16277191

Cc1ccc(COc2ccc(CO[C@@H]3C[C@@H](C(=O)NCc4ccc(Cl)cc4)N(C(=O)OCC4c5ccccc5-c5ccccc54)C3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.39
▸ HDAC1 Q13547 2/20 0.39
▸ FFAR2 O15552 2/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ CFD P00746 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ KMT2A Q03164 1/20 0.36
▸ MCL1 Q07820 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ POLB P06746 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ GRM5 P41594 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16277190 0.85 FFAR2 (0.45) LMNAFFAR2
SCHEMBL15111798 0.82 CFD (0.41) CFDKMT2AMCL1POLBALDH1A1
SCHEMBL15111797 0.82 CFD (0.41) CFDKMT2AMCL1POLBALDH1A1
SCHEMBL8166482 0.81 AGTR2 (0.42) FFAR2CYP3A4CYP2C9CYP2C19KMT2A
SCHEMBL15126387 0.81 FFAR2 (0.36) FFAR2KMT2AALDH1A1
SCHEMBL16095440 0.74 AGTR2 (0.48) KMT2A
SCHEMBL21874030 0.74 AGTR2 (0.48) KMT2A
SCHEMBL21553619 0.74 AGTR2 (0.48) KMT2A
SCHEMBL31210291 0.74 AGTR2 (0.48) KMT2A
SCHEMBL5963754 0.74 AGTR2 (0.48) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2014-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140356322-A1 Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase VHL, MDM2, STUB1 LMNA 2962/4885HDAC1 1489/4885FFAR2 4760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback